PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-8.57%
Both companies show declining cash positions (-8.57% vs RVPH's -10.03%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-8.57%
Cash + STI yoy 0.75-0.9x RVPH's -10.03%. Bill Ackman would wonder if competitor is building liquidity more aggressively.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-16.59%
Other current assets growth < half of RVPH's -100.00%. David Dodd sees a leaner approach to short-term items.
-8.67%
1.25-1.5x RVPH's -5.85%. Bruce Berkowitz checks if strong current asset growth is used effectively.
-8.20%
Both RVPH and the company show zero PP&E (Net) Growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1.26%
Higher Other Non-Current Assets Growth compared to RVPH's zero value, indicating worse performance.
-7.12%
Both RVPH and the company show zero Total Non-Current Assets Growth.
No Data
No Data available this quarter, please select a different quarter.
-8.62%
≥ 1.5x RVPH's -5.25%. David Dodd notes a larger balance sheet expansion. Confirm it's not overleveraged.
-100.00%
Less than half of RVPH's 87.02%. David Dodd sees a more disciplined AP approach or lower volume.
-100.00%
Above 1.5x RVPH's -60.00%. Michael Burry sees a major discrepancy in short-term leverage. Check coverage and liquidity carefully.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1405.81%
Less than half of RVPH's -3.72%. David Dodd sees fewer expansions in other current obligations.
-20.28%
Less than half of RVPH's 25.75%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-0.40%
Less than half of RVPH's -48.15%. David Dodd sees a more conservative approach to non-current liabilities.
No Data
No Data available this quarter, please select a different quarter.
-4.61%
Less than half of RVPH's 24.96%. David Dodd sees far fewer liability expansions relative to competitor.
No Data
No Data available this quarter, please select a different quarter.
-3.23%
0.5-0.75x RVPH's -5.59%. Martin Whitman is wary of weaker retention or lower profitability.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-12.84%
Below half RVPH's -65.22%. Michael Burry sees potential underperformance in building shareholder capital.
-8.62%
≥ 1.5x RVPH's -5.25%. David Dodd sees faster overall balance sheet growth than competitor.
-100.00%
Both RVPH and the company show zero Total Investments Growth.
-7.46%
Less than half of RVPH's -60.00%. David Dodd sees less overall debt expansion vs. competitor.
8.60%
Similar yoy changes to RVPH's 8.29%. Walter Schloss sees parallel net leverage strategies.